pharmaphorum
AUGUST 11, 2024
The FDA has denied Lykos Therapeutics' marketing application for its post-traumatic stress disorder (PTSD) therapy based on MDMA, also known as ecstasy, in a setback for the emerging psychedelic medicines category.
Drug Patent Watch
AUGUST 11, 2024
Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five NDAs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
JAMA Internal Medicine
AUGUST 11, 2024
This cohort study evaluated the associations of plant and animal fat intake with cardiovascular disease and overall mortality outcomes.
Drug Patent Watch
AUGUST 11, 2024
Annual Drug Patent Expirations for NINLARO Ninlaro is a drug marketed by Takeda Pharms Usa and is included in one NDA. It is available from one supplier. There are nine patents protecting this drug.
FDA Law Blog
AUGUST 11, 2024
By Sarah Wicks & Dara Katcher Levy — FDA’s Office of Prescription Drug Promotion (OPDP) has issued two new Untitled Letters this summer after 5 months without any letter activity. The letters are vastly different from one another in subject matter, but together they make a cruel summer of OPDP enforcement against industry. [Editorial note – the Gen X’er included that link first – for the arguably more popular reference, read on.
Drug Patent Watch
AUGUST 11, 2024
The development of generic drugs is a crucial aspect of the pharmaceutical industry, as it provides affordable alternatives to expensive […] Source
Expert insights. Personalized for you.
73 
Let's personalize your content